The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...
Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...
The small miracles that 2024 brought to our lives lay the groundwork for new revolutionary treatments that are being prepared ...
Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things to look for include more widespread adoption of artificial intelligence ...
Medpage Today on MSN12dOpinion
CMS Moved to Expand Obesity Drug Coverage. Private Insurers Need to Step Up.This proposed rule signals an important shift in the federal approach to obesity management, aligning with the medical ...
Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...
Although bipartisan legislation to provide Medicare coverage for obesity treatments has circulated in Congress for more than ...
Lisa Jarvis In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish ...
Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...
The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback